Why Applied DNA Sciences (APDN) Stock Is Rising
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2025
0mins
Source: Benzinga
Stock Performance: Applied DNA Sciences Inc (APDN) shares rose by 6.0% to $1.76 after announcing its TR8 PGx pharmacogenomics testing as pre-emptive testing for therapeutic safety, specifically targeting patients with DPYD gene variants.
Future Plans: The company plans to enhance its TR8 PGx testing service with additional specialized subpanels in oncology, cardiology, and psychiatry to improve clinical decision-making and promote the adoption of pharmacogenomics testing.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
